Small-molecule inhibitor of Fam20C in combination with paclitaxel suppresses tumor growth by LIF-JAK2/STAT3-modulated apoptosis in triple-negative breast cancer

Yuan, Zhaoxin; Zhen, Yongqi; Chen, Siwei; Li, Zixiang; Fu, Leilei

doi:10.1016/j.jtice.2023.104673

Cited by 1 publication

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, combination therapy has been suggested as a means of preventing and overcoming drug resistance, which aims to improve efficacy through drug synergy and to lessen the frequency and severity of side effects by reduced doses of individual drugs [24,25]. Several drugs have been reported to combinate with paclitaxel in cancer [26], such as atezolizumab [27,28] and resveratrol [29]. In addition, some studies have found that flubendazole can enhance the cytotoxicity of fluorouracil and adriamycin by inhibiting tubulin polymerization and inducing the formation of monopolar spindle in breast cancer [30].…”

Section: Discussionmentioning

confidence: 99%

Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer

Zhou,

Liao,

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Paclitaxel, a natural anticancer drug, is widely recognized and extensively utilized in the treatment of breast cancer (BC). However, it may lead to certain side effects or drug resistance. Fortunately, combination therapy with another anti-tumor agent has been explored as an option to improve the efficacy of paclitaxel in the treatment of BC. Herein, we first evaluated the synergistic effects of paclitaxel and flubendazole through combination index (CI) calculations. Secondly, flubendazole was demonstrated to synergize paclitaxel-mediated BC cell killing in vitro and in vivo. Moreover, we discovered that flubendazole could reverse the drug resistance of paclitaxel-resistant BC cells. Mechanistically, flubendazole was demonstrated to enhance the inhibitory effect of paclitaxel via HIF1α/PI3K/AKT signaling pathways. Collectively, our findings demonstrate the effectiveness of flubendazole in combination with paclitaxel for treating BC, providing an insight into exploiting more novel combination therapies for BC in the future.

show abstract